RT Journal Article
SR Electronic
T1 Factors Predicting Recurrence in Patients with Siewert Type II Carcinoma Treated with Curative Resection
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 505
OP 509
VO 35
IS 1
A1 MINORU FUKUCHI
A1 ERITO MOCHIKI
A1 OKIHIDE SUZUKI
A1 TORU ISHIGURO
A1 JUN SOBAJIMA
A1 HISASHI ONOZAWA
A1 HIDEKO IMAIZUMI
A1 KAZUE SHIBATA
A1 KANA SAITO
A1 HIROSHI NAITOH
A1 YOUICHI KUMAGAI
A1 KEIICHIRO ISHIBASHI
A1 HIDEYUKI ISHIDA
YR 2015
UL http://ar.iiarjournals.org/content/35/1/505.abstract
AB Aim: To evaluate the recurrence risk for Siewert type II esophagogastric junction carcinoma treated with curative resection. Patients and Methods: We retrospectively analyzed clinicopathological and recurrence-free survival (RFS) data of 52 patients after curative resection for Siewert type II carcinoma focusing on the role of lymph node metastasis around the greater curvature or parapyloric area. Results: Recurrence was observed in 21 (40%) patients; the median time-to-recurrence was 11 months (range=3-33 months). According to multivariate Cox proportional hazard regression analysis, involvement of nodes no. 4sa, 4sb, 4d, 5 and/or 6 (odds ratio (OR)=6.62; 95% confidence interval (CI)=1.27-41.1; p=0.04) and younger age (OR=2.10; 95% CI=1.25-3.82; p<0.01) were significant independent risk factors affecting RFS. Conclusion: Involvement of no. 4-6 nodes appears to predict recurrence of Siewert type II carcinoma treated with curative resection. Patients with this risk factor may benefit from effective use of perioperative chemotherapy.